"2015-01-22+01:00"^^ . "2013-03-26+01:00"^^ . . " treatment modalities" . "Detection of HPV in the oropharyngeal cancer prior to treatment selects the group of HPV positive and negative patients. In both groups a treatment response and survival rate for various treatment modalities (chemotherapy, radiotherapy, chemoradiotherapy, biological treatment with monoclonal antibodies, surgery) will be analysed. We would determine whether the prognostic advantage of patients with HPV positive tumours is treatment modality dependent. We suppose, that HPV positive patients could benefit from a less intensive non-surgical therapy with an equal survival rate. HPV status could soon become a tool for treatment individualisation. Direct (HPV DNA, HPV mRNA of E6 and E 2 genes) and indirect (p53, p16 proteins) markers of an active viral infection will be detected and sensitivity of HPV DNA detection by means of ISH and PCR would be compared. With the aim to find out the optimal diagnostic method for selection of patients with HPV related head and neck cancers in clinical setting."@en . " prognosis" . "0"^^ . . "2011-06-01+02:00"^^ . "http://www.isvav.cz/projectDetail.do?rowId=NT12483"^^ . . . "Relation of viral etiology of oropharyngeal tumors to the response rate of individual treatment modalities"@en . . "2014-12-31+01:00"^^ . . . "oropharyngeal cancer; human papillomavirus; prognosis; treatment modalities; methods of HPV detection"@en . "Vztah virov\u00E9 etiologie n\u00E1dor\u016F orofaryngu k \u00FAsp\u011B\u0161nosti jednotliv\u00FDch l\u00E9\u010Debn\u00FDch modalit" . " human papillomavirus" . . . . . . . "3"^^ . "3"^^ . . "1"^^ . . "oropharyngeal cancer" . . . "Stanoven\u00ED HPV ve vzorku orofarynge\u00E1ln\u00EDho dla\u017Edicobun\u011B\u010Dn\u00E9ho karcinomu p\u0159ed l\u00E9\u010Dbou selektuje skupinu pacient\u016F s HPV pozitivn\u00EDmi a negativn\u00EDmi n\u00E1dory. V obou skupin\u00E1ch bude zji\u0161\u0165ov\u00E1na l\u00E9\u010Debn\u00E1 odpov\u011B\u010F a p\u0159e\u017Eit\u00ED v z\u00E1vislosti na l\u00E9\u010Debn\u00FDch modalit\u00E1ch (chemoterapie, radioterapie, chemoradioterapie, biologick\u00E1 l\u00E9\u010Dba monoklon\u00E1ln\u00ED protil\u00E1tkou, chirurgie). Bude zkoum\u00E1no, zda prognostick\u00E1 v\u00FDhoda HPV pozitivity je v\u00E1z\u00E1na na zp\u016Fsob l\u00E9\u010Dby. P\u0159edpokl\u00E1d\u00E1me, \u017Ee HPV pozitivn\u00ED pacienti by do budoucna mohli profitovat z m\u00E9n\u011B intenzivn\u00ED konzervativn\u00ED terapie p\u0159i zachov\u00E1n\u00ED stejn\u00E9 progn\u00F3zy. HPV status by se v kr\u00E1tk\u00E9m \u010Dasov\u00E9m horizontu mohl st\u00E1t v\u00FDznamn\u00FDm n\u00E1strojem pro stratifikaci l\u00E9\u010Dby. Detekov\u00E1ny budou p\u0159\u00EDm\u00E9 (HPV DNA, HPV mRNA genu E6 a E2) a nep\u0159\u00EDm\u00E9 (exprese protein\u016F p53 a p16) markery aktivn\u00ED virov\u00E9 infekce a bude srovn\u00E1na senzitivita metod stanovuj\u00EDc\u00EDch p\u0159\u00EDtomnost HPV DNA -PCR a ISH. \u00DA\u010Delem je zji\u0161t\u011Bn\u00ED optim\u00E1ln\u00ED diagnostick\u00E9 metody pro klinickou praxi k selekci pacient\u016F s HPV pozitivn\u00EDmi n\u00E1dory hlavy a krku." . "2"^^ . "NT12483" .